Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody. ALE.C04 is indicated to treat patients with recurrent or metastatic CLDN1-positive head and neck squamous cell carcinoma (HNSCC). Fast Track designation aims to facilitate the development and expedite the review of new […]
